About
Technology
Issues
FAQ
Links
Official Page
LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.